<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DURAMORPH- morphine sulfateÂ injectionÂ </strong><br>West-Ward Pharmaceutical Corp.<br></p></div>
<h1><span class="Bold"><span class="Bold">PRESERVATIVE-FREE</span><br>Duramorph (morphine sulfate injection, USP)<br><span class="Bold"><span class="Bold">CII<br>Rx only<br></span></span><span class="Bold">Not For Use in Continuous Microinfusion Devices</span><br><br></span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_fff678f1-7c20-440f-bf61-8dd204974531"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Morphine is the most important alkaloid of opium and is a phenanthrene derivative. It is available as the sulfate salt, having the following structural formula:</p>
<div class="Figure"><img alt="Duramorph Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-1.jpg"></div>
<p>7,8-Didehydro-4,5-epoxy-17-methyl-(5Î±,6Î±)-morphinan-3,6-diol sulfate (2:1) (salt),Â pentahydrate</p>
<p>(C<span class="Sub">17</span>H<span class="Sub">19</span>NO<span class="Sub">3</span>)<span class="Sub">2</span>â€¢ H<span class="Sub">2</span>SO<span class="Sub">4</span>â€¢ 5H<span class="Sub">2</span>OÂ Molecular Weight is 758.83</p>
<p>Preservative-free DURAMORPH (morphine sulfate injection, USP) is a sterile, nonpyrogenic, isobaric solution of morphine sulfate, free of antioxidants, preservatives or other potentially neurotoxic additives and is intended for intravenous, epidural or intrathecal administration as a narcotic analgesic. Each milliliter contains morphine sulfate 0.5Â mg or 1Â mg and sodium chloride 9Â mg in Water for Injection. pH range is 2.5â€‘6.5. Each 10Â mLÂ ampul of DURAMORPH is intended for <span class="Bold">SINGLE USE ONLY.</span><span class="Italics"> Discard any unused portion.</span> DO NOT HEAT-STERILIZE.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_1b54e42e-6c5a-438d-8b96-3a61ad151038"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Morphine produces a wide spectrum of pharmacologic effects including <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, diminished gastrointestinal motility and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Opiate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> involves at least three anatomical areas of the central nervous system: the periaqueductal-periventricular gray matter, the ventromedial medulla and the spinal cord. A systematically administered opiate may produce <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> by acting at any, all or some combination of these distinct regions. Morphine interacts predominantly with the Î¼-receptor. The Î¼-binding sites of opioids are very discretely distributed in the human brain, with high densities of sites found in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve.</p>
<p>Morphine has an apparent volume of distribution ranging from 1.0 to 4.7Â L/kg after<span class="Italics"> intravenous</span> dosage<span class="Italics">.</span> Protein binding is low, about 36%, and muscle tissue binding is reported as 54%. A blood-brain barrier exists, and when morphine is introduced outside of the CNS (e.g.,<span class="Italics">intravenously</span>), plasma concentrations of morphine remain higher than the corresponding CSF morphine levels. Conversely, when morphine is injected into the <span class="Italics">intrathecal space</span>, it diffuses out into the systemic circulation slowly, accounting for the long duration of action of morphine administered by this route.</p>
<p>Morphine has a total plasma clearance which ranges from 0.9 to 1.2Â L/kg/h (liters/kilogram/hour) in postoperative patients, but shows considerable interindividual variation. The major pathway of clearance is hepatic glucuronidation to morphineâ€‘3â€‘glucuronide, which is pharmacologically inactive. The major excretion path of the conjugate is through the kidneys, with about 10% in the feces. Morphine is also eliminated by the kidneys, 2 to 12% being excreted unchanged in the urine. Terminal half-life is commonly reported to vary from 1.5 to 4.5 hours, although the longer halfâ€‘lives were obtained when morphine levels were monitored over protracted periods with very sensitive radioimmunoassay methods. The accepted elimination half-life in normal subjects is 1.5 to 2 hours.</p>
<p>â€œSelectiveâ€? blockade of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> sensation is possible by neuraxial application of morphine. In addition, duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> may be much longer by this route compared to systemic administration. However, CNS effects, associated with systemic administration, are still seen. These include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. In particular, both early and late <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (up to 24 hours post dosing) have been reported following neuraxial administration. Circulation of the spinal fluid may also result in high concentrations of morphine reaching the brain stemÂ directly.</p>
<p>The incidence of unwanted CNS effects, including delayed <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, associated with neuraxial application of morphine, is related to the circulatory dynamics of the epidural venous plexus and the spinal fluid. The lipid solubility and degree of ionization of morphine plays an important part in both the onset and duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and the CNS effects. Morphine has a pK<span class="Sub">a</span> 7.9, with an octanol/water partition coefficient of 1.42 at pH 7.4. At this pH, the tertiary amino group in each of the opioids is mostly ionized, making the molecule water soluble. Morphine, with additional hydroxyl groups on the molecule, is significantly more water soluble than any other opioid in clinical use.</p>
<p>Morphine, injected into the <span class="Italics">epidural space</span>, is rapidly absorbed into the general circulation. Absorption is so rapid that the plasma concentration-time profiles closely resemble those obtained after intravenous or intramuscular administration. Peak plasma concentrations averaging 33â€“40Â ng/mL (range 5â€“62Â ng/mL) are achieved within 10 to 15 minutes after administration of 3 mg of morphine. Plasma concentrations decline in a multiexponential fashion. The terminal half-life is reported to range from 39 to 249 minutes (mean of 90 Â± 34.3 min) and, though somewhat shorter, is similar in magnitude as values reported after intravenous and intramuscular administration (1.5â€“4.5 h). CSF concentrations of morphine, after epidural doses of 2 to 6Â mg in postoperative patients, have been reported to be 50 to 250 times higher than corresponding plasma concentrations. The CSF levels of morphine exceed those in plasma after only 15 minutes and are detectable for as long as 20 hours after the injection of 2 mg of epidural morphine. Approximately 4% of the dose injected epidurally reaches the CSF. This corresponds to the relative minimum effective epidural and intrathecal doses of 5Â mg and 0.25Â mg, respectively. The disposition of morphine in the CSF follows a biphasic pattern, with an early half-life of 1.5 h and a late phase half-life of about 6 h. Morphine crosses the dura slowly, with an absorption half-life across the dura averaging 22 minutes. Maximum CSF concentrations are seen 60â€“90 minutes after injection. Minimum effective CSF concentrations for postoperative <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> average 150Â ng/mL (rangeÂ &lt;Â 1â€‘380 ng/mL).</p>
<p>The <span class="Italics">intrathecal route</span> of administration circumvents meningeal diffusion barriers and, therefore, lower doses of morphine produce comparable <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> to that induced by the epidural route. After intrathecal bolus injection of morphine, there is a rapid initial distribution phase lasting 15â€“30 minutes and a half-life in the CSF of 42â€“136 min (mean 90 Â± 16 min). Derived from limited data, it appears that the disposition of morphine in the CSF, from 15 minutes postintrathecal administration to the end of a six-hour observation period, represents a combination of the distribution and elimination phases. Morphine concentrations in the CSF averaged 332 Â± 137Â ng/mL at 6 hours, following a bolus dose of 0.3 mg of morphine. The apparent volume of distribution of morphine in the intrathecal space is about 22 Â± 8Â mL.</p>
<p>Time-to-peak plasma concentrations, however, are similar (5-10 min) after either epidural or intrathecal bolus administration of morphine. Maximum plasma morphine concentrations after 0.3 mg intrathecal morphine have been reported from &lt; 1 to 7.8Â ng/mL. The minimum analgesic morphine plasma concentration during Patientâ€‘Controlled <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (PCA) has been reported as 20â€“40Â ng/mL, suggesting that any analgesic contribution from systemic redistribution would be minimal after the first 30â€“60 minutes with epidural administration and virtually absent with intrathecal administration of morphine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_04ce9433-1742-4206-aec9-147ecaa6b139"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">DURAMORPH is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> not responsive to non-narcotic analgesics. DURAMORPH administered epidurally or intrathecally, provides <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief for extended periods without attendant loss of motor, sensory or sympathetic function.</p>
<p><span class="Bold">Not For Use in Continuous Microinfusion Devices</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_554e6195-569b-45d0-8317-f8366b7409f6"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">DURAMORPH is contraindicated in those medical conditions which would preclude the administration of opioids by the intravenous routeâ€”<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to morphine or other opiates, acute bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, upper airway obstruction.</p>
<p>DURAMORPH, like all opioid analgesics, may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume or a concurrent administration of drugs, such as phenothiazines or general anesthetics. (See also <span class="Bold"><a href="#LINK_e57f61f6-6440-4173-9d0e-0cbc39e3d767">PRECAUTIONS: Use with Other Central Nervous System Depressants</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_5fd97c11-01a9-4eb0-bdb8-b45d9d1db88e"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Morphine sulfate may be habit forming. (See <span class="Bold"><a href="#LINK_95c2cd5f-57e1-4429-8e27-d63158f2cf36">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>.) <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>DURAMORPH administration should be limited to use by those familiar with the management of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Rapid intravenous administration may result in chest wall <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>.</p>
<p><span class="Bold">Prior to any epidural or intrathecal drug administration, the physician should be familiar with patient conditions (such as <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the injection site, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, anticoagulant therapy, etc.) which call for special evaluation of the benefit versus risk potential.</span></p>
<p>In the case of epidural or intrathecal administration, DURAMORPH should be administered by or under the direction of a physician experienced in the techniques and familiar with the patient management problems associated with epidural or intrathecal drug administration. Because epidural administration has been associated with less potential for immediate or late adverse effects than intrathecal administration, the epidural route should be used whenever possible.</p>
<p>SEVERE <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> UP TO 24 HOURS FOLLOWING EPIDURAL OR INTRATHECAL ADMINISTRATION HAS BEEN REPORTED.</p>
<table>
<col>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Toprule" valign="top">Â </td>
<td class="Botrule Toprule">Â  <span class="Bold">BECAUSE OF THE RISK OF SEVERE ADVERSE EFFECTS WHEN THE EPIDURAL OR INTRATHECAL ROUTE OF ADMINISTRATION IS EMPLOYED, PATIENTS MUST BE OBSERVED IN A FULLY EQUIPPED AND STAFFED ENVIRONMENT FOR AT LEAST 24 HOURS AFTER THE INITIALÂ DOSE</span>. </td>
<td class="Botrule Rrule Toprule" valign="top">Â </td>
</tr></tbody>
</table>
<p>THE FACILITY MUST BE EQUIPPED TO RESUSCITATE PATIENTS WITH SEVERE OPIATE OVERDOSAGE, AND THE PERSONNEL MUST BE FAMILIAR WITH THE USE AND LIMITATIONS OF SPECIFIC NARCOTIC ANTAGONISTS (NALOXONE, NALTREXONE) IN SUCH CASES.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_05183cae-ff1b-43ef-892d-3868ad2ec8d8"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">Tolerance and Myoclonic Activity</span></h2>
<p class="First">PATIENTS SOMETIMES MANIFEST UNUSUAL ACCELERATION OF NEURAXIAL MORPHINE REQUIREMENTS, WHICH MAY CAUSE CONCERN REGARDING SYSTEMIC ABSORPTION AND THE HAZARDS OF LARGE DOSES; THESE PATIENTS MAY BENEFIT FROM HOSPITALIZATION AND DETOXIFICATION. TWO CASES OF MYOCLONIC-LIKE SPASM OF THE LOWER EXTREMITIES HAVE BEEN REPORTED IN PATIENTS RECEIVING MORE THAN 20 MG/DAY OF INTRATHECAL MORPHINE. AFTER DETOXIFICATION, IT MIGHT BE POSSIBLE TO RESUME TREATMENT AT LOWER DOSES, AND SOME PATIENTS HAVE BEEN SUCCESSFULLY CHANGED FROM CONTINUOUS EPIDURAL MORPHINE TO CONTINUOUS INTRATHECAL MORPHINE. REPEAT DETOXIFICATION MAY BE INDICATED AT A LATER DATE. THE UPPER DAILY DOSAGE LIMIT FOR EACH PATIENT DURING CONTINUING TREATMENT MUST BE INDIVIDUALIZED.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_23ff9c1c-e79b-4404-9387-894591cd14f8"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Control of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> by neuraxial opiate delivery is always accompanied by considerable risk to the patients and requires a high level of skill to be successfully accomplished. The task of treating these patients must be undertaken by experienced clinical teams, well-versed in patient selection, evolving technology and emerging standards of care. For safety reasons, it is recommended that administration of DURAMORPH by the epidural or intrathecal routes be limited to the lumbar area. Intrathecal use has been associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> than epidural use.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> may result from high doses. Patients with known <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders should be carefully observed for evidence of morphine-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb39b479-53f9-41d3-ab6b-b5944aee52b8"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Use in Patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span></span></h2>
<p class="First">DURAMORPH should be used with extreme caution in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. Pupillary changes (<span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>) from morphine may obscure the existence, extent and course of intracranial pathology. High doses of neuraxial morphine may produce myoclonic events (see <span class="Bold"><a href="#LINK_5fd97c11-01a9-4eb0-bdb8-b45d9d1db88e">WARNINGS</a></span> and <span class="Bold"><a href="#LINK_9b09c1e6-f9d9-40b8-b3fc-a94a22e24c0b">ADVERSE REACTIONS</a></span>). Clinicians should maintain a high index of suspicion for adverse drug reactions when evaluating altered mental status or movement abnormalities in patients receiving this modality of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9f2217c5-bebb-4d80-a355-4e84b4861056"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Use in Chronic Pulmonary Disease</span></h2>
<p class="First">Care is urged in using this drug in patients who have a decreased respiratory reserve (e.g., <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, kyphoscoliosis or <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the phrenic nerve). DURAMORPH should not be given in cases of chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, upper airway obstruction or in any other chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary disorder</span> without due consideration of the known risk of <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> following morphine administration in such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d1ecb916-8970-4fd8-9f82-e35fafc2bd28"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">Use in Hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span></h2>
<p class="First">The elimination half-life of morphine may be prolonged in patients with reduced metabolic rates and with hepatic and/or renal dysfunction. Hence, care should be exercised in administering DURAMORPH epidurally to patients with these conditions,Â since high blood morphine levels, due to reduced clearance, may take severalÂ days to develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9a42b4f4-583a-460e-a008-72e3fa23ecfd"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Use in Biliary Surgery or Disorders of the Biliary Tract</span></h2>
<p class="First">As significant morphine is released into the systemic circulation from neuraxial administration, the ensuing smooth muscle <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> may result in <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5fa52f2b-4ade-441a-94eb-f4035b7d7fa4"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Use with Disorders of the Urinary System</span></h2>
<p class="First">Initiation of neuraxial opiate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is frequently associated with disturbances of micturition, especially in males with prostatic enlargement. Early recognition of difficulty in urination and prompt intervention in cases of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> is indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6fe8e767-6c8c-40ac-b72e-3cd367f526f1"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">Use in Ambulatory Patients</span></h2>
<p class="First">Patients with reduced circulating blood volume, impaired myocardial function or on sympatholytic drugs should be monitored for the possible occurrence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, a frequent complication in single-dose neuraxial morphine <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e57f61f6-6440-4173-9d0e-0cbc39e3d767"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold">Use with Other Central Nervous System Depressants</span></h2>
<p class="First">The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics or psychotropic drugs. Use of neuroleptics in conjunction with neuraxial morphine may increase the risk of respiratoryÂ <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_c58c1be4-b00d-4b60-a7c8-6eb8a9ecc6bc"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Morphine is without known carcinogenic or mutagenic effects and is not known to impair fertility at non-narcotic doses in animals, but studies of the carcinogenic and mutagenic potential or the effect on fertility of DURAMORPH have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_3687389e-2a7e-4239-95cf-998a763d0d37"></a><a name="section-6.10"></a><p></p>
<h2><span class="Bold">Pregnancy</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_12714127-b9f1-4526-a37f-8064491e854b"></a><a name="section-6.10.1"></a><p></p>
<h3>
<span class="Bold">TERATOGENIC </span><span class="Bold">EFFECTS - PREGNANCYÂ CATEGORY C.</span>
</h3>
<p class="First">Morphine sulfate is not teratogenic in rats at 35Â mg/kg/day (thirty-five times the usual human dose) but does result in increased pup mortality and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> at doses that narcotize the animal (&gt; 10Â mg/kg/day, ten times the usual human dose). DURAMORPH should only be given to pregnant women when no other method of controlling <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is available and means are at hand to manage the delivery and perinatal care of the opiate-dependent infant.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_e8caee60-8264-4c66-b606-5548c4dce684"></a><a name="section-6.10.2"></a><p></p>
<h3><span class="Bold">NONTERATOGENIC EFFECTS.</span></h3>
<p class="First">Infants born to mothers who have been taking morphine chronically may exhibit withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_df42f4ea-59c4-4d7d-8783-4c5bbc70905d"></a><a name="section-6.11"></a><p></p>
<h2><span class="Bold">Labor and Delivery</span></h2>
<p class="First"><span class="Italics">Intravenous</span> morphine readily passes into the fetal circulation and may result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate. Naloxone and resuscitative equipment should be available for reversal of narcotic-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate. In addition, intravenous morphine may reduce the strength, duration and frequency of uterine contraction resulting in <span class="product-label-link" type="condition" conceptid="434714" conceptname="Prolonged second stage of labor">prolonged labor</span>.</p>
<p><span class="Italics">Epidurally and intrathecally</span> administered morphine readily passes into the fetal circulation and may result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> of the neonate. Controlled clinical studies have shown that<span class="Italics"> epidural</span> administration has little or no effect on the relief of labor <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_f1514ec5-e8b5-4f8c-90fd-df78c54d34fc"></a><a name="section-6.12"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Morphine is excreted in maternal milk. Effects on the nursing infant are not known.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_b045184d-9b85-40aa-8f50-df3dac099728"></a><a name="section-6.13"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Adequate studies, to establish the safety and effectiveness of spinal morphine in pediatric patients, have not been performed, and usage in this population is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_3e59c15a-bb48-4d48-ab30-c0fce1608fc2"></a><a name="section-6.14"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">The pharmacodynamic effects of neuraxial morphine in the elderly are more variable than in the younger population. Patients will vary widely in the effective initial dose, rate of development of tolerance and the frequency and magnitude of associated adverse effects as the dose is increased. Initial doses should be based on careful clinical observation following â€œtest dosesâ€?, after making due allowances for the effects of the patientâ€™s age and infirmity on his/her ability to clear the drug, particularly in patients receiving epidural morphine.</p>
<p>Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> following administration of morphine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_9b09c1e6-f9d9-40b8-b3fc-a94a22e24c0b"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The most serious adverse experience encountered during administration of DURAMORPH is <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. This <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> may be severe and could require intervention. (See <span class="Bold"><a href="#LINK_5fd97c11-01a9-4eb0-bdb8-b45d9d1db88e">WARNINGS</a></span> and <span class="Bold"><a href="#LINK_f63a7f2c-e86b-4210-a5b4-28d55b119bc1">OVERDOSAGE</a></span>.) Because of delay in maximum CNS effect with intravenously administered drug (30 min), rapid administration may result in overdosing. Single-dose neuraxial administration may result in acute or delayed <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> for periods at least as long as 24 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e671ecaa-11ae-47d6-8796-72809f6bd46e"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">Tolerance and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>:</span></h2>
<p class="First">See <span class="Bold"><a href="#LINK_5fd97c11-01a9-4eb0-bdb8-b45d9d1db88e">WARNINGS</a></span> for discussion of these and related hazards.</p>
<p>While low doses of intravenously administered morphine have little effect on cardiovascular stability, high doses are excitatory, resulting from <span class="Bold">sympathetic <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span></span> and increase in circulating catecholamines. Excitation of the central nervous system, resulting in <span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></span>, may accompany high doses of morphine given intravenously.<span class="Bold"> Dysphoric reactions</span> may occur after any size dose and <span class="Bold">toxic psychoses</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ac8ab998-9068-4660-abba-d374acd4282f"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>:</span></h2>
<p class="First">Single-dose epidural or intrathecal administration is accompanied by a high incidence of <span class="Bold"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></span> that is dose-related but not confined to the site of administration. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, following continuous infusion of epidural or intrathecal morphine, is occasionally reported in the literature; these reactions are poorly understood as to their cause.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_14346be4-1abf-436f-94c2-e103f9828d5c"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, which may persist 10 to 20 hours following single epidural or intrathecal administration, is a frequent side effect and must be anticipated primarily in male patients, with a somewhat lower incidence in females. Also frequently reported in the literature is the occurrence of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> during the first several days of hospitalization for the initiation of continuous intrathecal or epidural morphine therapy. Patients who develop <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have responded to cholinomimetic treatment and/or judicious use of catheters (see <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2a10b0fd-3624-4329-b49a-c647a13500c0"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is frequently encountered during continuous infusion of morphine; this can usually be managed by conventional therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_19c4ff35-0506-400f-8f65-e5e726c52f08"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>:</span></h2>
<p class="First">Lumbar puncture-type <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> is encountered in a significant minority of cases for several days following intrathecal catheter implantation; this, generally, responds to bed rest and/or other conventional therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6b61fcc0-0c89-468f-80f1-523ba4f5f8fb"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Other:</span></h2>
<p class="First">Other adverse experiences reported following morphine therapy includeâ€”<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, reduced male potency, decreased libido in men and women, and menstrual irregularities including <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex, interference with thermal regulation</span> and <span class="Bold"><span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span></span>. Evidence of histamine release such as <span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span></span> and/or <span class="Bold">local tissue irritation</span> may occur. <span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span> and <span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span> are frequently seen in patients following morphine administration.</p>
<p><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, if associated with continuous infusion therapy, may respond to intravenous administration of a low dose of naloxone (0.2Â mg). The risks of using narcotic antagonists in patients chronically receiving narcotic therapy should be considered.</p>
<p>In general, side effects are amenable to reversal by narcotic antagonists.</p>
<table>
<col>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Toprule" valign="top">Â </td>
<td class="Botrule Toprule">Â <span class="Bold">NALOXONE INJECTION AND RESUSCITATIVE EQUIPMENT SHOULD BE IMMEDIATELY AVAILABLE FOR ADMINISTRATION IN CASE OF LIFE-THREATENING OR INTOLERABLE SIDE EFFECTS AND WHENEVER DURAMORPH THERAPY IS BEING INITIATED.</span>
</td>
<td class="Botrule Rrule Toprule" valign="top">Â </td>
</tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_95c2cd5f-57e1-4429-8e27-d63158f2cf36"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_2a1229ab-004c-4a62-857c-a5785d1785f4"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">Controlled Substance</span></h2>
<p class="First">Morphine sulfate is a Schedule II narcotic under the United States Controlled Substance Act (21 U.S.C. 801-886).</p>
<p>Morphine is the most commonly cited prototype for narcotic substances that possess an addiction-forming or addiction-sustaining liability. A patient may be at risk for developing a <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to morphine if used improperly or for overly long periods of time. As with all potent opioids which are Î¼-agonists, tolerance as well as psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to morphine may develop irrespective of the route of administration (intravenous, intramuscular, intrathecal, epidural or oral). Individuals with a prior history of opioid or other <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, being more apt to respond to the euphorogenic and reinforcing properties of morphine, would be considered to be at greater risk.</p>
<p>Care must be taken to avert withdrawal in patients who have been maintained on parenteral/oral narcotics when epidural or intrathecal administration is considered. Withdrawal symptoms may occur when morphine is discontinued abruptly or upon administration of a narcotic antagonist.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_f63a7f2c-e86b-4210-a5b4-28d55b119bc1"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First"><span class="Bold">PARENTERAL ADMINISTRATION OF NARCOTICS IN PATIENTS RECEIVING EPIDURAL OR INTRATHECAL MORPHINE MAY RESULT IN OVERDOSAGE.</span></p>
<p>Overdosage of morphine is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, with or without concomitant <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. Since <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> may result either through direct <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the respiratory center or as the result of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, primary attention should be given to the establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted, or controlled, ventilation. The narcotic antagonist, naloxone, is a specific antidote. An initial dose of 0.4 to 2Â mg of naloxone should be administered intravenously, simultaneously with respiratory resuscitation. If the desired degree of counteraction and improvement in respiratory function is not obtained, naloxone may be repeated at 2- to 3-minute intervals. If no response is observed after 10 mg of naloxone has been administered, the diagnosis of narcotic-induced, or partial narcotic-induced, toxicity should be questioned. Intramuscular or subcutaneous administration may be used if the intravenous route is not available.</p>
<p>As the duration of effect of naloxone is considerably shorter than that of epidural or intrathecal morphine, repeated administration may be necessary. Patients should be closely observed for evidence of renarcotization.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_7841dd1c-9118-4e8b-bd69-3eda12d2c9b3"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">DURAMORPH is intended for intravenous, epidural or intrathecal administration.</p>
<p><span class="Bold">Not For Use in Continuous Microinfusion Devices</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6da0914c-1a93-440b-b477-51565d404d6d"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold">Intravenous Administration</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0d03a1cd-f529-4d7f-a91e-479459ff0c2f"></a><a name="section-10.1.1"></a><p></p>
<h3>DOSAGE:</h3>
<p class="First">The initial dose of morphine should be 2 mg to 10 mg/70 kg of body weight. No information is available regarding the use of DURAMORPH in patients under the ageÂ ofÂ 18.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_99f803c4-11d0-4bed-83db-88eee9d58d0d"></a><a name="section-10.1.1.1"></a><p></p>
<h4><span class="Italics">Geriatric Use -</span></h4>
<p class="First">Administer with extreme caution. (See <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b5f6ae5d-2cbd-49b8-8b24-8b6572426406"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold">Epidural Administration</span></h2>
<p class="First">DURAMORPH SHOULD BE ADMINISTERED EPIDURALLY BY OR UNDER THE DIRECTION OF A PHYSICIAN EXPERIENCED IN THE TECHNIQUE OF EPIDURAL ADMINISTRATION AND WHO IS THOROUGHLY FAMILIAR WITH THE LABELING. IT SHOULD BE ADMINISTERED ONLY IN SETTINGS WHERE ADEQUATE PATIENT MONITORING IS POSSIBLE. RESUSCITATIVE EQUIPMENT AND A SPECIFIC ANTAGONIST (NALOXONE INJECTION) SHOULD BE IMMEDIATELY AVAILABLE FOR THE MANAGEMENT OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AS WELL AS COMPLICATIONS WHICH MIGHT RESULT FROM INADVERTENT INTRATHECAL OR INTRAVASCULAR INJECTION. (NOTE: INTRATHECAL DOSAGE IS USUALLY 1/10 THAT OF EPIDURAL DOSAGE.) <span class="Bold">PATIENT MONITORING SHOULD BE CONTINUED FOR AT LEAST 24 HOURS AFTER EACH DOSE, SINCE DELAYED <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> MAY OCCUR.</span></p>
<p>Proper placement of a needle or catheter in the epidural space should be verified before DURAMORPH is injected.</p>
<p>Acceptable techniques for verifying proper placement include: a) <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to check for absence of blood or cerebrospinal fluid, or b) administration of 5Â mL (3Â mL in obstetric patients) of 1.5% PRESERVATIVE-FREE Lidocaine and Epinephrine (1:200,000) Injection and then observe the patient for lack of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (this indicates that vascular injection has <span class="Italics">not</span> been made) and lack of sudden onset of segmental anesthesia (this indicates that intrathecal injection has <span class="Italics">not</span> been made).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4e95ade1-227f-4c92-9561-7c804c0832f1"></a><a name="section-10.2.1"></a><p></p>
<h3>EPIDURAL ADULT DOSAGE:</h3>
<p class="First">Initial injection of 5 mg in the lumbar region may provide satisfactory <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief for up to 24 hours. If adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not achieved within one hour, careful administration of incremental doses of 1 to 2Â mg at intervals sufficient to assess effectiveness may be given. No more than 10Â mg/24 hr should be administered.</p>
<p>Thoracic administration has been shown to dramatically increase the incidence of early and late <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> even at doses of 1 to 2Â mg.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e3d73158-c966-4c86-a660-0247676594be"></a><a name="section-10.2.1.1"></a><p></p>
<h4><span class="Italics">Geriatric Use -</span></h4>
<p class="First">Administer with extreme caution. (See <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_831f8b7d-789f-4af7-9f44-93e4b55e3e31"></a><a name="section-10.2.2"></a><p></p>
<h3><span class="Bold">EPIDURAL PEDIATRIC USE:</span></h3>
<p class="First">No information on use in pediatric patients is available. (See <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c23180c6-fa86-4fc5-93d7-6cc263717f6f"></a><a name="section-10.3"></a><p></p>
<h2><span class="Bold">Intrathecal Administration</span></h2>
<table>
<col>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Toprule" valign="top">Â </td>
<td class="Botrule Toprule">Â <span class="Bold">NOTE: INTRATHECAL DOSAGE IS USUALLY 1/10 THAT OF EPIDURALÂ DOSAGE.</span>
</td>
<td class="Botrule Rrule Toprule" valign="top">Â </td>
</tr></tbody>
</table>
<p class="First">DURAMORPH SHOULD BE ADMINISTERED INTRATHECALLY BY OR UNDER THE DIRECTION OF A PHYSICIAN EXPERIENCED IN THE TECHNIQUE OF INTRATHECAL ADMINISTRATION AND WHO IS THOROUGHLY FAMILIAR WITH THE LABELING. IT SHOULD BE ADMINISTERED ONLY IN SETTINGS WHERE ADEQUATE PATIENT MONITORING IS POSSIBLE. RESUSCITATIVE EQUIPMENT AND A SPECIFIC ANTAGONIST (NALOXONE INJECTION) SHOULD BE IMMEDIATELY AVAILABLE FOR THE MANAGEMENT OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AS WELL AS COMPLICATIONS WHICH MIGHT RESULT FROM INADVERTENT INTRAVASCULAR INJECTION. <span class="Bold">PATIENT MONITORING SHOULD BE CONTINUED FOR AT LEAST 24 HOURS AFTER EACH DOSE, SINCE DELAYED <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> MAY OCCUR.</span> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> (BOTH EARLY AND LATE ONSET) HAS OCCURRED MORE FREQUENTLY FOLLOWING INTRATHECAL ADMINISTRATION THAN EPIDURAL ADMINISTRATION.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b37aec71-e579-4243-8a92-1f073e114363"></a><a name="section-10.3.1"></a><p></p>
<h3>INTRATHECAL ADULT DOSAGE:</h3>
<p class="First">A single injection of 0.2 to 1Â mg may provide satisfactory <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief for up to 24 hours. (CAUTION: THIS IS ONLY 0.4 TO 2 ML OF THE 5 MG/10 ML AMPUL OR 0.2 TO 1Â ML OF THE 10 MG/10 ML AMPUL OF DURAMORPH). DO NOT INJECT INTRATHECALLY MORE THAN 2Â ML OF THE 5Â MG/10Â ML AMPUL OR 1 ML OF THE 10Â MG/10Â ML AMPUL. USE IN THE LUMBAR AREA ONLY IS RECOMMENDED. Repeated intrathecal injections of DURAMORPH are not recommended. A constant intravenous infusion of naloxone, 0.6Â mg/hr, for 24 hours after intrathecal injection may be used to reduce the incidence of potential side effects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_20f2624a-ebf4-4c5e-9d70-af900f192b54"></a><a name="section-10.3.1.1"></a><p></p>
<h4><span class="Italics">Geriatric Use -</span></h4>
<p class="First">Administer with extreme caution. (See <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a8727208-7229-42a0-b734-935b7d6daad3"></a><a name="section-10.3.2"></a><p></p>
<h3><span class="Bold">REPEAT DOSAGE:</span></h3>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> recurs, alternative routes of administration should be considered, since experience with repeated doses of morphine by the intrathecal route is limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_24bfb2ae-c935-430e-9860-1cea84c052a0"></a><a name="section-10.3.3"></a><p></p>
<h3>INTRATHECAL PEDIATRIC USE:</h3>
<p class="First">No information on use in pediatric patients is available. (See <span class="Bold"><a href="#LINK_ad1e0fbb-02ab-4561-b5f2-c85617cf914e">PRECAUTIONS</a></span>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0cad4efd-a0f9-499b-978e-f4dc115fa9b2"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">SAFETY AND HANDLING INSTRUCTIONS</span></h1>
<table>
<col>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Toprule" valign="top">Â </td>
<td class="Botrule Toprule" valign="top">
<p class="First">Â DURAMORPH is supplied in sealed ampuls. Accidental dermal exposure should be treated by the removal of any contaminated clothing and rinsing the affected area withÂ water.<br><br>Each ampul of DURAMORPH contains a potent narcotic which has been associated with abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> among health care providers. <span class="Bold">Due to the limited indications for this product, the risk of overdosage and the risk of its diversion and abuse, it is recommended that special measures be taken to control this product within the hospital or clinic.Â </span></p>
<p><span class="Bold"><span class="Italics">DURAMORPH should be subject to rigid accounting, rigorous control of wastage and restricted access.</span></span><br><br><span class="Bold">Parenteral drug products should be inspected for particulate matter and discoloration prior to administration, whenever solution and container permit. DO NOT USE IF COLOR IS DARKER THAN <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">PALE</span> YELLOW, IF IT IS DISCOLORED IN ANY OTHER WAY OR IF IT CONTAINS A PRECIPITATE.</span></p>
</td>
<td class="Botrule Rrule Toprule" valign="top">Â </td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_e3ef27b6-5baa-4866-8fc5-94d971956b08"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Preservative-Free DURAMORPH (morphine sulfate injection, USP) is available in amberÂ ampuls for intravenous, epidural and intrathecal administration:</p>
<p>5Â mg/10Â mL (0.5Â mg/mL) packaged in 10s (NDC 0641-6020-10)</p>
<p>10Â mg/10Â mL (1Â mg/mL) packaged in 10s (NDC 0641-6019-10)</p>
<p>Also available from West-Ward: INFUMORPH (Preservative-free Morphine Sulfate Sterile Solution) 200Â mg/20Â mL (10Â mg/mL) and 500Â mg/20Â mL (25Â mg/mL) for epidural and intrathecal administration via a continuous microinfusion device.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_95fa9757-9002-497f-96c9-e35bcf4610cd"></a><a name="section-13"></a><p></p>
<h1>STORAGE</h1>
<p class="First"><span class="Bold">PROTECT FROM LIGHT. Store in carton at 20Â°- 25Â°C (68Â°- 77Â°F), excursions permitted to 15Â°- 30Â°C (59Â°- 86Â°F) [See USP Controlled Room Temperature] until ready to use. DO NOT FREEZE.</span> DURAMORPH contains no preservative or antioxidant. DISCARD ANY UNUSED PORTION. DO NOT HEAT-STERILIZE.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0887a795-9211-49a3-b2c1-62d9d00e95fd"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or <a href="#medwatch">www.fda.gov/medwatch</a>.</p>
<p>For Product Inquiry call 1-877-845-0689.</p>
<p>Manufactured by:</p>
<div class="Figure"><img alt="West-Ward Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-2.jpg"></div>
<p><span class="Bold">WEST-WARD<br></span>PHARMACEUTICALS<br>Eatontown, NJ 07724 USA</p>
<p>Revised August 2011</p>
<p>462-212-03</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ddc88484-2c5b-4364-9d15-048d69c5ead9"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">NDC 0641-6020-01<br><span class="Bold">PRESERVATIVE-FREE<br>Duramorph<br></span>(morphine sulfate injection, USP)<br><span class="Bold">CII<br>5 mg/10 mL (0.5 mg/mL)<br></span>10 mL Ampul<br><span class="Bold">Rx only<br>FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL<br>ADMINISTRATION-Read Package Insert Carefully<br></span>Each mL contains morphine sulfate 0.5 mg and sodium<br>chloride 9 mg in Water for Injection. pH 2.5-6.5<br><span class="Bold">PROTECT FROM LIGHT</span>. Do not use if color is darker<br>than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any other way or<br>if it contains a precipitate.Â  DO NOT HEAT-STERILIZE.<br><br><img alt="NDC 0641-6020-01 PRESERVATIVE-FREE Duramorph (morphine sulfate injection, USP) CII 5 mg/10 mL (0.5 mg/mL) 10 mL Ampul Rx only FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL ADMINISTRATION-Read Package Insert Carefully Each mL contains morphine sulfate 0.5 mg and sodium chloride 9 mg in Water for Injection. pH 2.5-6.5 PROTECT FROM LIGHT. Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any other way or if it contains a precipitate. DO NOT HEAT-STERILIZE." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-3.jpg"></p>
<p>NDC 0641-6020-10<br><span class="Bold">Rx only<br>PRESERVATIVE-FREE<br>Duramorph (morphine sulfate injection, USP)Â Â Â CII<br>5 mg/10 mL<br> (0.5 mg/mL)<br>FOR INTRAVENOUS,<br>EPIDURAL OR INTRATHECAL<br>ADMINISTRATION<br>10 x 10 mL Ampuls<br></span>Each mL contains morphine sulfate 0.5 mg and sodium<br>chloride 9 mg in Water for Injection. pH 2.5-6.5.<br><span class="Bold">Usual Dosage and Adminstration:</span> Read Package Insert.<br><span class="Bold">PROTECT FROM LIGHT: Keep covered in carton until time of use.<br>Store at 20Âº-25ÂºC (68Âº-77ÂºF), excursions permitted<br>to 15Âº-30ÂºC (59Âº-86ÂºF) [See USP Controlled Room<br>Temperature].<br></span>Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is<br>discolored in any way or if it contains a precipitate.<br>CONTAINS NO PRESERVATIVE. Discard any unused<br>portion.Â  DO NOT HEAT-STERILIZE.<br>To open ampuls, ignore color line; break at constriction.</p>
<div class="Figure"><img alt="NDC 0641-6020-10 Rx only PRESERVATIVE-FREE Duramorph (morphine sulfate injection, USP) CII 5 mg/10 mL (0.5 mg/mL) FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL ADMINISTRATION 10 x 10 mL Ampuls Each mL contains morphine sulfate 0.5 mg and sodium chloride 9 mg in Water for Injection. pH 2.5-6.5. Usual Dosage and Adminstration: Read Package Insert. PROTECT FROM LIGHT: Keep covered in carton until time of use. Store at 20Âº-25ÂºC (68Âº-77ÂºF), excursions permitted to 15Âº-30ÂºC (59Âº-86ÂºF) [See USP Controlled Room Temperature]. Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any way or if it contains a precipitate. CONTAINS NO PRESERVATIVE. Discard any unused portion. DO NOT HEAT-STERILIZE. To open ampuls, ignore color line; break at constriction." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_709dcc1b-4903-408e-a9ee-b14557ebd8a3"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">NDC 0641-6019-01<br><span class="Bold">PRESERVATIVE-FREE<br>Duramorph (morphine sulfate injection, USP)<br>CII<br>10 mg/10 mL (1 mg/mL)<br></span>10 mL Ampul<br><span class="Bold">Rx only<br>FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL<br>ADMINISTRATION-Read Package Insert Carefully<br></span>Each mL contains morphine sulfate 1 mg and sodium<br>chloride 9 mg in Water for Injection.Â pH 2.5-6.5.<br><span class="Bold">PROTECT FROM LIGHT.</span> Do not use if color is darker<br>than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any other way or<br>if it contains a precipitate. DO NOT HEAT-STERILIZE.</p>
<div class="Figure"><img alt="NDC 0641-6019-01 PRESERVATIVE-FREE Duramorph (morphine sulfate injection, USP) CII 10 mg/10 mL (1 mg/mL) 10 mL Ampul Rx only FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL ADMINISTRATION-Read Package Insert Carefully Each mL contains morphine sulfate 1 mg and sodium chloride 9 mg in Water for Injection. pH 2.5-6.5. PROTECT FROM LIGHT. Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any other way or if it contains a precipitate. DO NOT HEAT-STERILIZE." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-5.jpg"></div>
<p>NDC 0641-6019-10<br><span class="Bold">Rx only<br>PRESERVATIVE-FREE<br>Duramorph (morphine sulfate injection, USP)Â  CII<br>10 mg/10 mL<br>(1 mg/mL)<br></span><span class="Bold">FOR INTRAVENOUS,<br>EPIDURAL OR INTRATHECAL<br>ADMINISTRATION<br>10 x 10 mL Ampuls<br></span>Each mL contains morphine sulfate 1 mg and sodium<br>chloride 9 mg in Water for Injection.Â pH 2.5-6.5.<br><span class="Bold">Usual Dosage and Administration:</span> Read Package Insert.<br><span class="Bold">PROTECT FROM LIGHT. Keep covered in carton until<br>time of use.<br>Store at 20Âº-25ÂºC (68Âº-77ÂºF), excursion permitted<br>to 15Âº-30ÂºC (59Âº-86ÂºF) [ See USP Controlled Room<br>Temperature].<br></span>Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is<br>discolored in any other way or if it contains a precipitate.<br>CONTAINS NO PERSERVATIVE.Â Discard any unused<br>portion. Â DO NOT HEAT-STERILIZE.<br>To open ampuls, ignore color line; break at constriction. </p>
<div class="Figure"><img alt="NDC 0641-6019-10 Rx only PRESERVATIVE-FREE Duramorph (morphine sulfate injection, USP) CII 10 mg/10 mL (1 mg/mL) FOR INTRAVENOUS, EPIDURAL OR INTRATHECAL ADMINISTRATION 10 x 10 mL Ampuls Each mL contains morphine sulfate 1 mg and sodium chloride 9 mg in Water for Injection. pH 2.5-6.5. Usual Dosage and Administration: Read Package Insert. PROTECT FROM LIGHT. Keep covered in carton until time of use. Store at 20Âº-25ÂºC (68Âº-77ÂºF), excursion permitted to 15Âº-30ÂºC (59Âº-86ÂºF) [ See USP Controlled Room Temperature]. Do not use if color is darker than <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, if it is discolored in any other way or if it contains a precipitate. CONTAINS NO PERSERVATIVE. Discard any unused portion. DO NOT HEAT-STERILIZE. To open ampuls, ignore color line; break at constriction." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210&amp;name=duramorph-6.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURAMORPHÂ 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-6020</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MORPHINE SULFATE</strong> (MORPHINE) </td>
<td class="formItem">MORPHINE SULFATE</td>
<td class="formItem">0.5Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6020-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6020-01</td>
<td class="formItem">10 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018565</td>
<td class="formItem">09/18/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURAMORPHÂ 		
					</strong><br><span class="contentTableReg">morphine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-6019</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INTRATHECAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MORPHINE SULFATE</strong> (MORPHINE) </td>
<td class="formItem">MORPHINE SULFATE</td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6019-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6019-01</td>
<td class="formItem">10 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018565</td>
<td class="formItem">09/18/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-Ward Pharmaceutical Corp.
							(946499746)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">West-ward Pharmaceutical Corp</td>
<td class="formItem"></td>
<td class="formItem">946499746</td>
<td class="formItem">ANALYSIS(0641-6020, 0641-6019), LABEL(0641-6020, 0641-6019), MANUFACTURE(0641-6020, 0641-6019)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bcdd3ec9-7474-4798-8e25-f308a5abbeba</div>
<div>Set id: ebb18761-e5c4-4238-bb84-f9549f500210</div>
<div>Version: 3</div>
<div>Effective Time: 20131104</div>
</div>
</div>Â <div class="DistributorName">West-Ward Pharmaceutical Corp.</div></p>
</body></html>
